Hjem › Akut myeloid leukæmi › Minnesota
Akut myeloid leukæmi kliniske forsøg i Minnesota
27 studier for Akut myeloid leukæmi søger deltagere på steder i Minnesota.
Byer i Minnesota
- Minneapolis20 studier
- Rochester12 studier
- Saint Paul6 studier
- Brooklyn Park6 studier
- Bloomington6 studier
- Duluth6 studier
Officiel studietekst (engelsk)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Riverwood Healthcare Center, Aitkin
- Mayo Clinic Health System in Albert Lea, Albert Lea
- Essentia Health - Baxter Clinic, Baxter
- og 48 flere
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 40 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- og 8 flere
RekruttererFase 2
Alder 18 til 59 · Alle køn · Opdateret 28. sep. 2026 · NCT05554393MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- og 8 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT05564390A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- University of Minnesota/Masonic Cancer Center, Minneapolis
RekruttererFase 1
Op til 21 år · Alle køn · Opdateret 23. sep. 2026 · NCT07012044Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- og 8 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- og 8 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Mercy Hospital, Coon Rapids
- Essentia Health - Deer River Clinic, Deer River
- Essentia Health Cancer Center, Duluth
- og 9 flere
RekruttererFase 2
Alder 18 til 59 · Alle køn · Opdateret 22. sep. 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
- Mayo Clinic in Rochester, Rochester
RekruttererFase 3
6 Months – 21 Years · Alle køn · Opdateret 17. sep. 2026 · NCT04293562Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Mayo Clinic, Rochester
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT04588922Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Rochester MN-MAYOMN, Rochester
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 2. sep. 2026 · NCT06652438The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
- University of Minnesota/Masonic Cancer Center, Minneapolis
- Mayo Clinic in Rochester, Rochester
RekruttererFase 1/2
Op til 22 år · Alle køn · Opdateret 25. aug. 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Masonic Cancer Center, Minneapolis
RekruttererFase 3
29 Days – 21 Years · Alle køn · Opdateret 24. aug. 2026 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Minnesota, Minneapolis
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 20. aug. 2026 · NCT07007312Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
- Masonic Cancer Center, Minneapolis
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 22. jul. 2026 · NCT07008638HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
- Masonic Cancer Center, Minneapolis
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 14. jul. 2026 · NCT06594445Allo HSCT Using RIC and PTCy for Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
RekruttererFase 2
Op til 75 år · Alle køn · Opdateret 6. jul. 2026 · NCT05805605Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Masonic Cancer Center at University of Minnesota, Minneapolis
RekruttererFase 2
Op til 60 år · Alle køn · Opdateret 25. jun. 2026 · NCT03314974A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Mayo Clinic in Rochester, Rochester
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 10. jun. 2026 · NCT03017820Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
- Mark Juckett, MD, Minneapolis
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 19. maj 2026 · NCT07591649MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
- Masonic Cancer Center at University of Minnesota, Minneapolis
RekruttererFase 2
Alder 2 til 75 · Alle køn · Opdateret 16. apr. 2026 · NCT07493538A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
- Mayo Clinic Comprehensive Cancer Center, Rochester
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 13. apr. 2026 · NCT05732103Backtracking Leukemia-Typical Somatic Mutations in Cord Blood
- University of Minnesota/Masonic Cancer Center, Minneapolis
RekruttererObservationsstudie
Op til 25 år · Alle køn · Opdateret 8. apr. 2026 · NCT05014165MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
- University of Minnesota Masonic Cancer Center, Minneapolis
RekruttererFase 2
Op til 60 år · Alle køn · Opdateret 6. apr. 2026 · NCT05735717Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy
- Mayo Clinic in Rochester, Rochester
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 1. apr. 2026 · NCT06279572A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University of Minnesota, Minneapolis
- Mayo Clinic - Rochester, Rochester
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. mar. 2026 · NCT05735184A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- Mayo Clinic, Rochester
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 9. feb. 2026 · NCT06950034Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- Mayo Clinic, Rochester
RekruttererFrivillige med god helbredstilstand velkomne
Alder 18 til 120 · Alle køn · Opdateret 25. jul. 2025 · NCT05237258Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.